This past year we’ve remained on course, executing a straightforward, purposeful strategy to advance our pipeline of four clinical-stage oncology candidates and build a strong foundation to deliver value to our stakeholders.
ME-401 is an oral, once-daily, selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor in clinical development for the treatment of B-cell malignancies. MEI owns worldwide rights in all countries except Japan, which we licensed to Kyowa Kirin Co. in 2018.
Voruciclib is an orally administered cyclin-dependent kinase (CDK) inhibitor differentiated by its potent in vitro inhibition of CDK9, in addition to CDK6, 4 and 1. The CDK family of proteins are important cell cycle regulators and CDK9 specifically has potential importance for treating certain B-cell and myeloid malignancies.
ME-344 is our novel and tumor selective, isoflavone-derived mitochondrial inhibitor drug candidate. It directly targets the OXPHOS complex 1, a pathway involved in ATP production in the mitochondria. Inhibiting ATP production via the mitochondria has potential to treat a wide variety of cancers, particularly in combination with other cancer therapies.
Pracinostat, which we licensed to Helsinn Healthcare, is an oral histone deacetylase (HDAC) inhibitor being evaluated in a pivotal Phase 3 global registration clinical trial for the treatment of adults with newly diagnosed acute myeloid leukemia who are unfit to receive intensive chemotherapy. Pracinostat is also being evaluated in a Phase 2 trial in patients with high or very high-risk myelodysplastic syndrome.
Daniel Gold, Ph.D.
President & Chief Executive Officer
September 19, 2019
Nasdaq Spotlight Interview: Hear Dan Gold talk about MEI and it’s pipeline of oncology drug candidates.